DISEASE INDICATIONS: Gynaecological Cancer
MANUFACTURER: Clovis Oncology, Inc.
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Rubraca is indicated for the treatment of women with advanced ovarian cancer who have received two or more prior lines of chemotherapy and have a deleterious BRCA mutation, as detected by an FDA-approved test.
